Septerna FY2025 EPS Forecast Lowered by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised Septerna's FY2025 earnings per share estimate significantly lower, from ($0.14) to ($1.90), while also projecting ($2.15) EPS for FY2026.
• Recently, Septerna reported a quarterly loss of ($0.56) per share, missing analysts' forecasts by ($0.51) and generating revenue of only $0.12 million compared to expected revenue of $22.50 million.
• Despite the negative earnings outlook, Septerna maintains an "Overweight" rating from Cantor Fitzgerald and has a consensus rating of "Moderate Buy" with a target price of $26.75.

Septerna, Inc. (NASDAQ:SEPN - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for Septerna in a report issued on Tuesday, August 12th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of ($1.90) for the year, down from their previous estimate of ($0.14). Cantor Fitzgerald currently has a "Overweight" rating and a $25.00 target price on the stock. The consensus estimate for Septerna's current full-year earnings is ($7.11) per share. Cantor Fitzgerald also issued estimates for Septerna's FY2026 earnings at ($2.15) EPS.

Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51). Septerna had a negative return on equity of 31.52% and a negative net margin of 12,053.03%. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $22.50 million.

SEPN has been the subject of several other research reports. Wells Fargo & Company boosted their price target on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a report on Friday, May 16th. HC Wainwright began coverage on shares of Septerna in a research report on Monday, June 23rd. They issued a "buy" rating and a $26.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Septerna has a consensus rating of "Moderate Buy" and a consensus price target of $26.75.

Septerna Stock Down 0.3%

Shares of SEPN stock opened at $11.66 on Thursday. Septerna has a 12-month low of $4.17 and a 12-month high of $28.99. The firm has a market capitalization of $519.55 million and a price-to-earnings ratio of -1.15. The firm has a fifty day moving average of $11.47 and a 200-day moving average of $9.27.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SEPN. Tower Research Capital LLC TRC acquired a new position in shares of Septerna during the 4th quarter worth approximately $25,000. Legal & General Group Plc acquired a new position in shares of Septerna during the 4th quarter worth approximately $42,000. Summit Investment Advisors Inc. bought a new stake in shares of Septerna during the 4th quarter worth approximately $45,000. KLP Kapitalforvaltning AS bought a new stake in shares of Septerna during the 1st quarter worth approximately $49,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Septerna during the 4th quarter worth approximately $52,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.